OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Backes on the FILM Trial in Endometrial Cancer

January 9th 2020

Floor J. Backes, MD, discusses the phase III FILM trial in endometrial cancer.

Dr. Goetz on the Use of ctDNA in the MONARCH-3 Trial in HR+/HER2- Breast Cancer

January 9th 2020

Matthew P. Goetz, MD, Mayo Clinic, discusses the use of circulating tumor DNA in the phase III MONARCH-3 trial in hormone receptor–positive, HER2-negative breast cancer.

Dr. Chang on the Evolution of Surgical Techniques in Prostate Cancer

January 9th 2020

Sam S. Chang, MD, MBA, discusses the evolution of surgical techniques in prostate cancer.

Dr Weinberg on Varying Treatment Options in Metastatic Colorectal Cancer

January 9th 2020

Benjamin Weinberg, MD, discusses varying treatment options for patients with metastatic colorectal cancer.

Dr. Barocas on Adjuvant Sunitinib in Renal Cell Carcinoma

January 9th 2020

Daniel A. Barocas, MD, MPH, FACS, discusses adjuvant TKI therapy in patients with renal cell carcinoma at high risk of recurrence following cytoreductive nephrectomy.

Dr. Paulson on the Utility of Liquid Biopsies Versus Tissue Biopsies

January 9th 2020

R. Steven Paulson, MD, discusses the utility of liquid biopsies versus tissue biopsies.

Dr. Schlumbrecht on the Challenges of Diagnosing Uterine Leiomyosarcoma

January 9th 2020

Matthew P. Schlumbrecht, MD, discusses ongoing challenges in diagnosing uterine leiomyosarcoma.

Dr. Mims on Performing Molecular Profiling at Diagnosis in AML

January 9th 2020

Alice S. Mims, MD, discusses up front molecular profiling in patients with newly diagnosed acute myeloid leukemia.

Dr. Heath on Recent Approvals in Nonmetastic Prostate Cancer

January 9th 2020

Elisabeth I. Heath, MD, FACP, discusses apalutamide, enzalutamide, and darolutamide, which have all been approved for use in nonmetastatic castration-resistant prostate cancer.

Dr. Chaudhry on Unmet Needs in Relapsed/Refractory Multiple Myeloma

January 9th 2020

Maria Chaudhry, MBBS, discusses unmet needs in relapsed/refractory multiple myeloma.

Dr. Leslie on Real-World Outcomes of Patients With CLL Treated With Acalabrutinib

January 8th 2020

Lori A. Leslie, MD, discusses a retrospective analysis of real-world patients with chronic lymphocytic leukemia who were treated with acalabrutinib (Calquence).

Dr. McCloskey on the Results of the ASCERTAIN Trial in MDS

January 8th 2020

James K. McCloskey II, MD, discusses the results of the phase III ASCERTAIN trial in myelodysplastic syndrome.

Dr. Goy on the Results of the FLYER Trial in DLBCL

January 8th 2020

Andre Goy, MD, MS, chief, discusses the results of the multicenter FLYER trial in patients with diffuse large B-cell lymphoma.

Dr. Rugo on Findings of Oral Paclitaxel With Encequidar in Metastatic Breast Cancer

January 8th 2020

Hope S. Rugo, MD, discusses results of a randomized phase III trial evaluating oral paclitaxel with encequidar in patients with metastatic breast cancer.

Dr. O'Malley on Remaining Questions in Ovarian Cancer

January 8th 2020

David O’Malley, MD, discusses remaining questions in the ovarian cancer field.

Dr. McDermott on the Use of PD-1 Inhibitor Combos in mRCC

January 8th 2020

David F. McDermott, MD, discusses the use of PD-1 inhibitors in combination with VEGF inhibitors and CTLA-4 inhibitors in metastatic renal cell carcinoma.

Dr. Rampal on Treatment Options in Polycythemia Vera

January 8th 2020

Raajit K. Rampal, MD, PhD, hematologic oncologist, Memorial Sloan Kettering Cancer Center, discusses treatment options in polycythemia vera.

Dr. Hwang on Choosing Agents for Prostate Cancer Treatment

January 8th 2020

Clara Hwang, MD, discusses factors that can be used to decide what agent to use in the frontline setting for patients with metastatic castration-sensitive or castration-resistant prostate cancer.

Dr. Chaudhry on DRd Triplet in Transplant-Ineligible Multiple Myeloma

January 7th 2020

Maria Chaudhry, MBBS, discusses the use of daratumumab (Darzalex), lenalidomide (Revlimid), and dexamethasone in transplant-ineligible patients with multiple myeloma.

Dr. Cusnir on the Utility of Regorafenib in Gastric Cancer

January 7th 2020

Mike Cusnir, MD, discusses the utility of regorafenib (Stivarga) in gastric cancer.